Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight

LAS VEGAS, April 28, 2020 /PRNewswire/ -- The growth of NSCLC Market is expected to increase due to increasing incident cases of NSCLC, continuous uptake of approved therapies mainly immune checkpoint inhibitors, increasing use of biomarker testing, probable entry of potential premium price emerging therapies and increasing awareness of mutations, among others.

https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from report are:

    --  As per the DelveInsight analysis, the total incident cases of NSCLC in
        the 7MM were observed to be 484,726 cases in the year 2017. These cases
        are expected to grow with a significant CAGR in the study period
        2017-2030.
    --  There are different types of treatment available for NSCLC; however,
        mainly 10 types of standard treatment are used, which include Surgery,
        Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser
        therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and
        Watchful waiting.
    --  The market size of NSCLC in the 7MM is expected to increase during study
        period. According to the estimates, the highest contribution in the
        market size of NSCLC is from the United States followed by Japan,
        Germany, and the UK.
    --  One of the most exciting developments in lung cancer medicine is the
        introduction of targeted treatments.

Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast

NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers. The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.

The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.

Click here to know more on Non-Small Cell Lung Cancer pipeline

NSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.

Drugs covered in the report are:-

There are several key players robustly involved in developing potential products such as

    --  Nazartinib (EGF816)
    --  Capmatinib (INC280)
    --  Tepmetko (tepotinib)
    --  Merestinib
    --  JNJ-61186372 (JNJ-6372)
    --  Vemurafenib Plus Cobimetinib
    --  X-396 (Ensartinib)
    --  Tedopi (OSE2101)
    --  Selpercatinib (LY3527723/ LOXO-292)
    --  SAR408701
    --  Braftovi (encorafinib) + Mektovi (binimetinib)
    --  PADCEV (enfortumab vedotin/ASG-22ME)
    --  Pralsetinib (BLU-667)
    --  TAK-788: Canakinumab (ACZ885)
    --  Avelumab (Bavencio)
    --  Veliparib (ABT-888): Sitravatinib (MGCD516)
    --  Tesevatinib
    --  Romiplostim: Cabozantinib
    --  Sym015
    --  AMG 510
    --  INCMGA00012 (MGA012)
    --  Libtayo (Cemiplimab)
    --  Bavituximab
    --  M7824 (Bintrafusp alfa)
    --  And many others

Key Players covered in the report are:-

    --  Novartis Pharmaceuticals
    --  Merck KGaA
    --  Eli Lilly and Company
    --  Janssen Research & Development
    --  Hoffmann-La Roche
    --  Xcovery
    --  BeyondSpring Pharmaceuticals
    --  OSE Immunotherapeutics
    --  Sanofi
    --  Pfizer
    --  Astellas Pharma
    --  Seattle Genetics
    --  Blueprint Medicines Corporation
    --  Takeda
    --  AbbVie
    --  Kadmon Corporation
    --  Amgen
    --  Symphogen
    --  Regeneron Pharmaceuticals
    --  Peregrine Pharmaceuticals
    --  Avid Bioservices
    --  GlaxoSmithKline

And many others

The report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.

The reasons for buying this report:

    --  The report proffers an overview of pathophysiology, various diagnostic
        approaches and NSCLC treatment algorithm, including detailed chapters
        for marketed products and emerging therapies.
    --  Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM
        covering the United States, EU5 (Germany, France, Italy, Spain, and the
        United Kingdom), and Japan from 2017-2030.
    --  Detailed historical and forecasted NSCLC market covering the United
        States, EU5 and Japan from 2017-2030.
    --  Pipeline analysis across different stages of development (Phase III and
        Phase II), different emerging trends and comparative analysis of
        pipeline products with comprehensive clinical profiles, key
        cross-competition, launch date along with product development
        activities.
    --  Detailed Non-Small Cell Lung Cancer market size by therapies, covering
        the United States, EU5 and Japan from 2017-2030.
    --  Reimbursement scenario and Key Opinion Leader ViewsTable of Contents



     
     1.     
     
     Key Insights



     
     2.     
     
     Executive Summary of NSCLC



     
     3.     
     
     SWOT Analysis of NSCLC



     
     4.         Non-Small Cell Lung Cancer Market Overview at a Glance



     
     5.     
     
     NSCLC Disease Background and Overview



     
     6.     
     
     NSCLC Diagnosis



     
     7.         Non-Small Cell Lung Cancer Epidemiology and Patient
                    Population


        7.1.   
     
     The United States Epidemiology



     
     8.     
     
     EU-5 Epidemiology


        8.1.   
     
     Germany


        8.2.   
     
     France


        8.3.   
     
     Italy


        8.4.   
     
     Spain


        8.5.   
     
     The United Kingdom



     
     9.     
     
     Japan Epidemiology



     
     10.        Non-Small Cell Lung Cancer Current Treatment Practices



     
     11.    
     
     Guideline of NSCLC



     
     12.    
     
     Unmet Needs of NSCLC



     
     13.    
     
     Key Endpoints in NSCLC Clinical Trials



     
     14.        Non-Small Cell Lung Cancer Marketed Therapies


        14.1.  
     
     Key Cross


        14.2.      Rozlytrek (Entrectinib): Hoffmann-La Roche (Genentech)


        14.3.  
     
     Imfinzi (Durvalumab): AstraZeneca


        14.4.      Opdivo (Nivolumab): Bristol-Myers Squibb


        14.5.      Tecentriq (Atezolizumab): Genentech/Hoffmann-La Roche


        14.6.  
     
     Keytruda (Pembrolizumab): Merck


        14.7.      Tafinlar(Dabrafenib)in Combination with
                    Mekinist(Trametinib): Novartis


        14.8.  
     
     Tagrisso(Osimertinib): AstraZeneca


        14.9.  
     
     Lorbrena/Lorviqua (Lorlatinib): Pfizer


        14.10. 
     
     Vizimpro(Dacomitinib): Pfizer


        14.11.     Alunbrig (Brigatinib): Takeda Pharmaceuticals


        14.12. 
     
     Alecensa (Alectinib): Hoffmann-La Roche


        14.13.     Vitrakvi (Larotrectinib): Bayer Healthcare


        14.14. 
     
     Portrazza (Necitumumab): Eli Lilly



     
     15.        Non-Small Cell Lung Cancer Emerging Therapies


        15.1.      Nazartinib (EGF816): Novartis Pharmaceuticals


        15.2.      Capmatinib (INC280): Novartis Pharmaceuticals


        15.3.  
     
     Tepmetko (tepotinib): Merck KGaA


        15.4.  
     
     Merestinib: Eli Lilly and Company


        15.5.      JNJ-61186372 (JNJ-6372): Janssen Research & Development


        15.6.      Lazertinib: Yuhan Corporation/ Janssen Research &
                    Development


        15.7.      Vemurafenib Plus Cobimetinib: Hoffmann-La Roche


        15.8.  
     
     X-396 (Ensartinib): Xcovery


        15.9.      Plinabulin: BeyondSpring Pharmaceuticals


        15.10.     Tedopi (OSE2101): OSE Immunotherapeutics


        15.11.     Selpercatinib (LY3527723/LOXO-292): Eli Lilly and Company


        15.12. 
     
     SAR408701: Sanofi


        15.13.     Braftovi (encorafinib) + Mektovi (binimetinib): Pfizer


        15.14.     PADCEV (enfortumab vedotin/ASG-22ME): Astellas Pharma/
                    Seattle Genetics


        15.15.     Pralsetinib (BLU-667): Blueprint Medicines Corporation


        15.16. 
     
     TAK-788: Takeda


        15.17.     Canakinumab (ACZ885): Novartis Pharmaceuticals


        15.18.     Avelumab (Bavencio): Merck KGaA and Pfizer


        15.19. 
     
     Veliparib (ABT-888): AbbVie


        15.20.     Sitravatinib (MGCD516): Mirati Therapeutics/Bristol-Myers
                    Squibb/Beigene


        15.21. 
     
     Tesevatinib: Kadmon Corporation


        15.22. 
     
     Romiplostim: Amgen


        15.23. 
     
     Cabozantinib: Exelixis/Ipsen/Takeda


        15.24. 
     
     Sym015: Symphogen


        15.25. 
     
     AMG 510: Amgen


        15.26.     INCMGA00012 (MGA012): Incyte Corporation/ Zai Lab Limited


        15.27.     Libtayo (Cemiplimab): Regeneron Pharmaceuticals


        15.28.     Bavituximab: Peregrine Pharmaceuticals/ Avid Bioservices,
                    Inc


        15.29.     M7824 (Bintrafusp alfa): GlaxoSmithKline/Merck KGaA



     
     16.    
     
     NSCLC Seven Major Market Analysis



     
     17.    
     
     PD-L1-Market Size



     
     18.    
     
     BRAF Mutation-Market Size



     
     19.    
     
     c-MET Mutation-Market Size



     
     20.    
     
     EGFR Mutation-Market Size



     
     21.    
     
     ALK-Mutation-Market Size



     
     22.        Market Access and Reimbursement of NSCLC Therapies



     
     23.    
     
     Market Drivers of NSCLC



     
     24.    
     
     Market Barriers of NSCLC



     
     25.    
     
     Appendix



     
     26.    
     
     DelveInsight Capabilities



     
     27.    
     
     Disclaimer



     
     28.    
     
     About DelveInsight

Request a Webex Demo to get a walk-through of the report: https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-market

Related Reports:

    --  Non-Small Cell Lung Cancer Epidemiology Forecast to 2030
    --  Non-Small Cell Lung Cancer Global API Manufacturers, Marketed and Phase
        III Drugs Landscape, 2020
    --  Non-Small Cell Lung Cancer Pipeline Insights, 2020

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakur
info@delveinsight.com
+91-9650213330
DelveInsight

View original content:http://www.prnewswire.com/news-releases/non-small-cell-lung-cancer-market-is-expected-to-increase-with-a-cagr-of-10-7-for-the-study-period-of-2017-2030-delveinsight-301048494.html

SOURCE DelveInsight Business Research, LLP